180 results
8-K
EX-3.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
of his death, resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his possession
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
stock compensation expense associated with the retirement of our former CEO in the fourth quarter of 2022.
Net income from continuing operations … associated with the retirement of our former CEO in the fourth quarter of 2022, and employee-related expenses.
In September 2023, Ligand spun out its
8-K
EX-10.1
utvwcfh
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-10.1
pv7xkb
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
S-3ASR
jkl7hx
30 Sep 22
Automatic shelf registration
4:17pm
S-3ASR
EX-1.2
bxi62g7zk
30 Sep 22
Automatic shelf registration
4:17pm
S-3ASR
EX-4.3
0e35gq pu
30 Sep 22
Automatic shelf registration
4:17pm
425
f88yj t7oay3wy
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-10.1
iag cfvuzjqp79azae
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.1
0l1sh2j5
24 Mar 22
Entry into a Material Definitive Agreement
9:08am